Navigation Links
NW Bio Reaches 30 Clinical Trial Sites Ahead of End-of-Q1 Projection
Date:2/23/2012

BETHESDA, Md., Feb. 23, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it now has 30 clinical trial sites open and recruiting across the United States in its ongoing Phase 2 clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.  The Company reached this milestone ahead of schedule, as the Company had projected to reach it by the end of Q1, 2012.  The Company likewise met or exceeded its projections in the three preceding quarters (Q2, Q3 and Q4 of 2011), as previously announced. 

(Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO)

The Company plans to continue adding clinical trial sites, and expects to have at least 40 sites open and enrolling by the end of Q2, 2012.  The Company will also continue pursuing its programs in Europe.  The open and active trial sites are listed on the U.S. Government's website, www.clinicaltrials.gov, and on NW Bio's website, www.nwbio.com

As previously stated, the Company's progress continues to reflect the growing interest from both physicians and patients, and a growing awareness of the positive data from the Company's prior clinical trials for GBM brain cancer.  In those trials, patients who received DCVax® showed a median survival of 3 years compared with median survival of 14.6 months for patients who received standard of care (surgery, radiation and chemotherapy).  Patients who received DCVax® also experienced a substantially longer time to tumor recurrence: a median of 2 years, compared with 6.9 months in patients who received standard of care.  DCVax® was well-tolerated, with no toxic side effects.

Linda Powers, CEO of NW Bio, commented that "Together with our r
'/>"/>

SOURCE Northwest Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
2. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
3. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
4. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
5. CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
6. Genmab Reaches Milestone in Ofatumumab Collaboration
7. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
8. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Ovarian Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
9. Catalyst Reaches Enrollment Target for its U.S. Phase II Cocaine Trial
10. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges
11. Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... Codman Neuro*, part of DePuy Synthes Companies ... of embolic coils for the treatment of brain aneurysms, ... microcatheter stability and provide an optimized detachment zone for ... the Society of NeuroInterventional Surgery (SNIS) 12 th ... and finishing coils used during a minimally invasive endovascular ...
(Date:7/28/2015)... IRVINE, Calif., July 28, 2015  Edwards Lifesciences Corporation (NYSE: ... of heart valves and hemodynamic monitoring, today reported net ... million, or $1.02 per diluted share.  Adjusted net income ... per diluted share, compared to $0.88 per diluted share ... period, GAAP net income was $5.09 per diluted share, ...
(Date:7/28/2015)... NASHVILLE, Tenn. , July 28, 2015 ... that it will release second quarter 2015 financial results ... A conference call and live Internet webcast will be ... Eastern Time to discuss the results. To ... callers) or 253-237-1032 (for international callers).  A rebroadcast of ...
Breaking Medicine Technology:Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 2Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 3Codman Neuro Launches Family Of Coils For Treatment Of Brain Aneurysms 4Edwards Lifesciences Reports Second Quarter Results 2Edwards Lifesciences Reports Second Quarter Results 3Edwards Lifesciences Reports Second Quarter Results 4Edwards Lifesciences Reports Second Quarter Results 5Edwards Lifesciences Reports Second Quarter Results 6Edwards Lifesciences Reports Second Quarter Results 7Edwards Lifesciences Reports Second Quarter Results 8Edwards Lifesciences Reports Second Quarter Results 9Edwards Lifesciences Reports Second Quarter Results 10Edwards Lifesciences Reports Second Quarter Results 11Edwards Lifesciences Reports Second Quarter Results 12Edwards Lifesciences Reports Second Quarter Results 13Edwards Lifesciences Reports Second Quarter Results 14Edwards Lifesciences Reports Second Quarter Results 15Edwards Lifesciences Reports Second Quarter Results 16Edwards Lifesciences Reports Second Quarter Results 17Edwards Lifesciences Reports Second Quarter Results 18Edwards Lifesciences Reports Second Quarter Results 19Edwards Lifesciences Reports Second Quarter Results 20Edwards Lifesciences Reports Second Quarter Results 21Edwards Lifesciences Reports Second Quarter Results 22Edwards Lifesciences Reports Second Quarter Results 23Cumberland Pharmaceuticals To Announce Second Quarter 2015 Financial Results 2
... Inc.,(Nasdaq: SUPG ), a pharmaceutical company ... of therapies for solid tumors and,hematological malignancies, ... the,European Hematology Association (EHA) in Copenhagen, Denmark, ... cell proliferation in,vivo (abstract #741)., In ...
... a,biopharmaceutical company focused on the discovery and development ... diseases,announced today that it has completed enrollment in ... or obese patients with high cholesterol and,triglycerides., ... the drug,s,effect on dyslipidemia and insulin resistance, and ...
Cached Medicine Technology:SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation 2Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:7/29/2015)... ... 2015 , ... Stealth Therapeutics Inc. announced today that it ... Invisiport at Wheaton Franciscan Healthcare in Milwaukee, Wis. The Invisiport product line, which ... alternative to traditional chest ports and peripherally inserted central catheters (PICCs). It is ...
(Date:7/29/2015)... ... ... Several years ago, in order to be in the strongest position possible to ... and began planning the Children’s Village consisting of six homes. , Two are already ... home. , “We are very pleased to have received the $500,000 grant from The ...
(Date:7/29/2015)... ... July 29, 2015 , ... TransFlip is an all new dynamic ... drop presets for FCPX, these transitions are easy to apply and modify for any ... transition. With over 60 preset styles, kinetic flipping panel animations are just a few ...
(Date:7/29/2015)... ... July 29, 2015 , ... Attorneys representing American families in ... Lawsuit Center. The website now features a page dedicated to news related to pending ... sources. The Talcum Powder Lawsuit News page was launched with eight initial ...
(Date:7/29/2015)... MO (PRWEB) , ... July 29, 2015 , ... ... of a decision from the Judicial Panel on Multidistrict Litigation (JPML), according to ... birth defects research at their website, the Zofran Birth Defects Lawsuit Center. , ...
Breaking Medicine News(10 mins):Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 2Health News:Stealth Therapeutics Inc. Enrolls First Patients in a Clinical Performance Study for the Invisiport Product Line 3Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 2Health News:Little City Receives $500,000 Matching Grant from The Coleman Foundation 3Health News:Pixel Film Studios Releases FCPX Transition TransFlip for FCPX 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 2Health News:National Attorneys Provide Regular Talcum Powder Lawsuit News Updates 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 2Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 3Health News:Zofran Lawsuit News: Zofran Lawsuits Stayed, Awaiting MDL Decision 4
... Children,s Hospital, Summit County ... to provide full-range of services to families with children who have ... Copley Township , , FAIRLAWN, Ohio, ... creation of the Robert J. Keegan Family Center for Autism. , , ...
... June 2009: Patients with rheumatic diseases want more information ... issues related to their conditions, according to the results ... the Annual Congress of the European League Against Rheumatism ... that, although nurses understand the importance of addressing sexual ...
... Denmark, Friday 12 June 2009: Over half (56%) of ... chronic inflammatory disease of the gum and surrounding ligaments ... fewer teeth than healthy matched controls, high prevalence of ... (the extent of periodontal support that has been destroyed ...
... directors of Abbott today declared a quarterly common dividend of 40 cents ... dividend to be paid by Abbott since 1924. The cash dividend ... of business on July 15, 2009. , , Abbott has increased ... increase earlier this year - and was again named to the ...
... SINGAPORE, June 12 /PRNewswire-Asia/ -- More ... speak in Singapore at the Healthcare,Travel Congress 2009 ... Sciences from 29 to 30 June 2009. These ... on medical tourism, with topics,varying from cross-border marketing, ...
... Coverage Protection and Information , , WARWICK, R.I., ... influenza pandemic have been met, the World ... to as Swine Flu, has reached pandemic stage. , ... , "Particularly in times of a worldwide pandemic, ...
Cached Medicine News:Health News:Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism 2Health News:Autism Family Foundation Introduces The Robert J. Keegan Family Center for Autism 3Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 2Health News:Better access to info and dialogue with HCPs on sexual issues for rheumatology patients 3Health News:Over half of people with rheumatoid arthritis have periodontitis 2Health News:Over half of people with rheumatoid arthritis have periodontitis 3Health News:Healthcare Travel Congress 2009: Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 2Health News:Healthcare Travel Congress 2009: Experts Worldwide Convene in Singapore For Regional Conference on Medical Tourism 3Health News:World Health Organization Declares A(H1N1) Pandemic 2Health News:World Health Organization Declares A(H1N1) Pandemic 3
... Add the perfect mix of powerful, ... practice, with the Palomar StarLux® Pulsed Light ... handpieces to one compact base unit ... systems for different treatments., You can choose ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... The Klein Pump provides ... requiring tumescent infiltration. Operates on ... off switch with safety Interlock ... Single Spike Tubing, Double Spike ...
Inquire...
Medicine Products: